DISEASE: Seronegative arthritis
Seronegative spondyloarthropathies (SpA) represent a group of chronic articular inflammatory diseases which differ from rheumatoid arthritis for the typical absence of rheumatoid factor in serum, and have in common several epidemiological, pathological, clinical, and radiological features. SpA include ankylosing spondylitis (AS), reactive arthritis (ReA), enteropathic (IBD) associated arthritis, psoriatic arthritis (PsA), as well as undifferentiated, and juvenile SpA. The main clinical manifestations include inflammatory back pain, peripheral arthritis, enthesitis, and extra-skeletal manifestations, such as uveitis. Although the cause of SpA is unknown, it is generally accepted that SpA is a multifactorial disease. Genetics (such as HLA-B27), inflammatory cytokines (such as TNF), and more recently the IL-23/IL-17 cytokine pathway have links to pathogenesis. Biologic agents, particularly TNF blockers, are primary treatment options and have been shown to reduce symptomatic inflammation.
Human diseases [BR:
Other musculoskeletal diseases
H01507 Seronegative arthritis
Triamcinolone acetonide [DR:
Dexamethasone sodium phosphate [DR:
Hydrocortisone sodium succinate [DR:
Prednisolone sodium phosphate [DR:
Methylprednisolone sodium succinate [DR:
Methylprednisolone acetate [DR:
Cortisone acetate [DR:
Certolizumab pegol [DR:
Paparo F, Revelli M, Semprini A, Camellino D, Garlaschi A, Cimmino MA, Rollandi GA, Leone A
Seronegative spondyloarthropathies: what radiologists should know.
Radiol Med 119:156-63 (2014)
Wilson G, Folzenlogen DD
Spondyloarthropathies: new directions in etiopathogenesis, diagnosis and treatment.
Mo Med 109:69-74 (2012)
Melis L, Elewaut D
Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?
Arthritis Res Ther 11:233 (2009)
» Japanese version
integrated database retrieval system